Your browser doesn't support javascript.
loading
Adverse events of COVID-19 vaccines in pregnant and postpartum women in Brazil: A cross-sectional study.
Covas, Dimas Tadeu; de Jesus Lopes de Abreu, Ariane; Zampirolli Dias, Carolina; Vansan Ferreira, Rafaela; Gonçalves Pereira, Ramon; Silva Julian, Guilherme.
Afiliação
  • Covas DT; Butantan Institute, São Paulo, Brazil.
  • de Jesus Lopes de Abreu A; IQVIA Brazil, São Paulo, Brazil.
  • Zampirolli Dias C; IQVIA Brazil, São Paulo, Brazil.
  • Vansan Ferreira R; IQVIA Brazil, São Paulo, Brazil.
  • Gonçalves Pereira R; IQVIA Brazil, São Paulo, Brazil.
  • Silva Julian G; IQVIA Brazil, São Paulo, Brazil.
PLoS One ; 18(1): e0280284, 2023.
Article em En | MEDLINE | ID: mdl-36638103
ABSTRACT

BACKGROUND:

By the fact that pregnant and postpartum women are currently using COVID-19 vaccines, ensure their safety is critical. So, more safety evidence is crucial to include this new technology to their vaccine's calendar and to develop public policies regarding the support and training of Health Care Personnel. This study aims to describe the adverse events (AE) of COVID-19 vaccines in pregnant and postpartum women in the early stage of vaccination campaign in Brazil.

METHODS:

An observational cross-sectional study using data from the Brazilian surveillance information system to characterize the AE of COVID-19 vaccines (Sinovac/Butantan, Pfizer/BioNTech, AstraZeneca and Janssen) in Brazilian pregnant and postpartum women from April to August 2021. Frequency and incidence rate of AE for COVID-19 vaccines were assessed.

RESULTS:

3,333 AE following immunization were reported for the study population. AE incidence was 309.4/100,000 doses (95% CI 297.23, 321.51). Within the vaccines available, Sinovac/Butantan had the lowest incidence (74.08/100,000 doses; 95% CI 63.47, 84.69). Systemic events were the most frequent notified (82.07%), followed by local (11.93%) and maternal (4.74%), being most of them classified as non-severe (90.65%).

CONCLUSION:

Our results corroborate the recommendation of vaccination for these groups. Even though, further studies appraising a longer observation time are still needed to provide a broader safety aspect for the vaccines currently under use for this population.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vacinas / Vacinas contra COVID-19 / COVID-19 Tipo de estudo: Observational_studies / Prevalence_studies / Risk_factors_studies Limite: Female / Humans / Pregnancy País como assunto: America do sul / Brasil Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vacinas / Vacinas contra COVID-19 / COVID-19 Tipo de estudo: Observational_studies / Prevalence_studies / Risk_factors_studies Limite: Female / Humans / Pregnancy País como assunto: America do sul / Brasil Idioma: En Ano de publicação: 2023 Tipo de documento: Article